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ABSTRACT 
Background: Stillbirth prevention is an international priority - risk prediction models could 
individualise care and reduce unnecessary intervention, but their use requires evaluation. 
Objectives: To identify risk prediction models for stillbirth, and assess their potential 
accuracy and clinical benefit in practice. 
Search strategy: Medline, EMBASE, DH-DATA and AMED databases were searched from 
inception to June 2019 using terms relevant to stillbirth, perinatal mortality and prediction models. 
The search was compliant with PRISMA guidelines.
Selection criteria: Studies developing and/or validating prediction models for risk of stillbirth 
developed for application during pregnancy. 
Data collection and analysis: Study screening and data extraction were conducted in 
duplicate, using the CHARMS checklist. Risk of bias was appraised using the PROBAST tool. 
Results: The search identified 2751 citations. Fourteen studies reporting development of 69 
models were included. Variables consistently included were: ethnicity, body mass index (BMI), 
uterine artery Doppler, pregnancy-associated plasma protein (PAPP-A) and placental growth 
factor (PlGF). Almost all models had significant concern about risk of bias. Apparent model 
performance (i.e. in the development dataset) was highest in models developed for use later 
in pregnancy and including maternal characteristics, and ultrasound and biochemical 
variables, but few were internally validated and none were externally validated. 
Conclusions: Almost all models identified were at high risk of bias. There are first trimester 
models of possible clinical benefit in early risk stratification; these require validation and clinical 
evaluation. There were few later pregnancy models, but if validated, these could be most relevant to 
individualised discussions around timing of birth.
Funding 
The authors are collaborators in the IPPIC (International Prediction of Pregnancy Complications) 
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INTRODUCTION
There is substantial patient and clinician interest in individualising obstetric care, and risk prediction 
models are proliferating.(1) Stillbirth accounts for more global deaths than HIV/AIDS or cancer; over 
2.6 million a year. (2) As reduction of stillbirth has become an international health policy priority, 
induction of labour rates have increased (3). Therefore, accurate risk stratification and 
individualisation of interventions for the prevention of stillbirth are a research priority in order to 
minimise iatrogenic harm and facilitate effective stillbirth prevention. 
As clinicians increasingly apply prediction models in practice, critical appraisal of model quality and 
clinical impact is crucial. Guidelines for robust model development and reporting exist to support best 
practice. (4,5) (6) In 2016, a systematic review reported on over 100 prognostic models developed 
for use in obstetrics.(1) Few were either internally or externally validated. Internal validation is crucial 
to estimate and, if necessary, adjust for optimism in apparent model performance in the development 
dataset. External validation evaluates predictive performance in a new independent dataset. Often a 
model provides less accurate predictions in a new population, and therefore continuous validation 
and updating of models for clinical use is necessary, as is systematic evaluation of clinical impact.(7) 
The aim of this review was to identify studies reporting on the development and/or validation of 
models for the prediction of stillbirth (intrauterine fetal death after 20 weeks’ gestation, encompassing 
all international definitions of stillbirth(8)) during pregnancy and assess their methodological quality 
and potential for further external validation and/or clinical use. 
METHODS
This review was conducted according to guidance from the Cochrane Prognosis Methods Group, 
and utilising the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction 
Modelling Studies (CHARMS) guidance.(4,9) The findings were reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).(10) This 
systematic review was prospectively registered with the PROSPERO database (Ref: 
CRD42018074788). Patients were not directly involved in the conduct of this study. The authors are 
collaborators in the IPPIC (International Prediction of Pregnancy Complications) stillbirth project, 
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We included models intended for use by maternity care providers at any time during pregnancy in 
either high or low resource settings. The expected aim of such models would be to select women for 
interventions, additional monitoring or scheduled birth (by induction of labour or planned Caesarean 
section) to prevent stillbirth.
Electronic searches were made of the Medline, EMBASE, Allied & Complementary Medicine and 
DH-DATA databases from inception to June 2019. The search included relevant terms for stillbirth, 
intrauterine fetal death and perinatal mortality combined with terms to increase sensitivity and 
specificity for prediction models, unrestricted by language.(11,12) (Appendix S1) Reference lists of 
included studies and studies citing existing systematic reviews of stillbirth prediction identified in the 
search were reviewed in order to identify additional potentially relevant papers to be included in 
abstract screening. 
We defined a prediction model as a model, score or clinical decision tool incorporating more than 
three variables to estimate the patient-specific risk of stillbirth. We defined variables included in 
model development as candidate predictors, and variables included in the final model as predictors. 
We included development and validation studies of any prediction model addressing the risk of 
stillbirth at any time in during pregnancy. We accepted and noted the authors’ definition of stillbirth 
because this varies between settings.(8) We excluded studies that assessed the first trimester 
screening ‘combined test’ as prediction tool for stillbirth, since this model was not developed for this 
purpose. We excluded studies exploring prediction of composite outcomes even where the 
composite included stillbirth, unless model performance for stillbirth alone was reported. 
Abstracts were screened, potentially eligible texts were retrieved and examined, and data extracted 
in duplicate (RT, AM). Data were extracted according to the CHARMS checklist.(4) Discrepancies 
were resolved by consensus. 
Every model reported was assessed using PROBAST criteria (5) (see Appendix S2) and an overall 
assessment of ‘high’ or ‘low’ risk of bias was made by consensus of both reviewers. PROBAST 
includes domains for model participants, predictors, outcomes and analysis. For the latter, 
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of model bias and subsequent underperformance in a new population. Model performance may be 
apparent (performance in the development dataset without adjustment for overfitting), validated 
internally (e.g. via bootstrap, cross or split sample validation) or externally (in an independent data 
set).  Performance measures include both discrimination (ability of the model to separate those who 
will develop the outcome of interest from those who will not) and calibration (difference between 
predicted and observed risks across the population and the whole range of predicted risk). (13)
A key variable in model development is the sample size, particularly the number of events per 
predictor parameter (EPP). The commonly held ‘rule of thumb’ is that >10 EPP minimises the risk of 
model overfitting.(14) However, the optimal sample size is actually context specific and may be 
higher or lower than 10,(15,16) taking into account outcome prevalence, the magnitude of predictor 
effects and the expected fit of the model (R2). (17–19) 
For the analysis, where multiple models were presented, the authors’ final recommended model was 
included. The results are presented as counts and percentages as indicated. If multiple validation 
reports of a single model were identified, we planned to undertake meta-analysis of model 
performance, but no such reports were identified. 
Extraction of performance statistics
For each model we extracted data on performance statistics including the c statistic or AUC (Area 
Under the receiver operating characteristic Curve), calibration in the large (CITL), and sensitivity and 
specificity at particular risk thresholds. We recorded the presentation of calibration plots and 
extracted calibration slope, mean absolute error and ‘goodness-of-fit’ where reported. Where these 
measures were not reported directly we did not seek to derive them indirectly from other information.
RESULTS
The literature search identified 2751 studies. Fifty-seven were selected for full text screening and 14 
papers (published 2007-2018) reporting 69 models were included. (Figure 1, Figure S1) The 
characteristics of the included studies are described in Table S1. No external validation studies were 
identified. Where development of multiple models was reported in one paper, this was because 
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developers varied candidate predictors because of their availability in the setting of intended use 
(20,21) or to investigate the contribution of novel predictors to model performance. (22,23) 
Three groups developed models using data derived from low-resource settings (20,21,24) while the 
remainder were developed in higher-resource settings. Most included all women presenting for 
routine pregnancy care. Some excluded women for whom delivery information was unavailable. 
(23,25–28) Several models were developed for high-risk populations – women admitted to 
hospital,(20) women with hypertension in pregnancy,(21)  high BMI (29) or women requiring third 
trimester fetal ultrasound.(30) One was developed using a low risk population excluding women with 
previous adverse obstetric outcomes, ‘infection’ and medical co-morbidities.(31) 
The predictors included in the final models are summarised in Table 1. In some studies the full set of 
candidate predictors was not clear.(24,32) The most frequently included predictor was ethnicity. 
Ethnicity was identified as a predictor of stillbirth in both univariable and multivariable analyses in 
every study that evaluated it, but was highly variable in classification, even among datasets from the 
same country and city. (Table S2) One group divided their population by country of birth (29), one by 
regionally specific ethnic groups (20) who would all have been classified as a single ethnicity in other 
models. One US based group classified as ‘Black, White or other’ while UK groups included one or 
more categories for Asian women. (25,31,33) Although ethnicity is likely to intersect with social 
disadvantage as a risk factor for stillbirth(34), only two studies(20,29) included measures of social 
disadvantage as candidate predictors. In one, occupation and rural residence were included with 
ethnicity in the final model as predictors.(20)
Maternal body mass index (BMI) and uterine artery pulsatility index (UtAPI) were also consistently 
included in prediction models when evaluated as candidate predictors. Three reports excluded 
ultrasound candidate predictors because they were not routinely available.(20,21,32) Other maternal 
characteristics included as predictors in the included models were smoking and alcohol use, 
maternal education, prior pregnancy loss, parity and place of residence. One model included 
‘maternal medical co-morbidities’ as a predictor (20) while others included individual conditions 
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Where biomarkers were evaluated, pregnancy-associated plasma protein A (PAPP-A) and placental 
growth factor (PlGF) each consistently contributed to prediction. Where they were compared directly, 
PlGF made a greater contribution to performance.(27) 
All identified models were developed for the prediction of stillbirth, but stillbirth was variably defined. 
No core outcome set (COS) for stillbirth research has yet been published, and researchers relied on 
national, international or customised outcome specifications. In all, 16 distinct stillbirth outcomes 
were reported across the 69 models (Table S3). The most common gestational cut off was >24 
weeks (range 20-34). Most studies excluded pregnancies affected by congenital anomaly and 
several excluded women who delivered spontaneously <24 weeks from the development data set. 
Some groups subclassified stillbirth by gestation (<32, <33, >33, <37 and >37 weeks of gestation) or 
categorised stillbirth by cause (unexplained or placentally associated). All identified models used 
either antepartum or ‘all stillbirth’; none predicted intrapartum stillbirth. 
Quality assessment 
The risk of bias and applicability of each of the models are reported in detail in Table S1 and 
summarised in Figures 2a and 2b. 
Description of clinical context and population was of a high standard. For some models there was 
concern about bias related to the unclear exclusion and inclusion criteria. In most, definition and 
measurement of candidate predictors and outcomes was acceptable. All included studies were 
retrospective and none included predictors masked from the clinical teams or outcome assessors, 
but knowledge of predictors would be unlikely to change determination of the outcome in this context. 
One study did not specify the candidate predictors used in model development.(32)
Almost all included models raised significant concern about risk of bias relating to conduct and 
reporting of the analysis. According to the PROBAST criteria, an EPP <10 flags potential for concern, 
whilst an EPP >20 indicates less potential for concern.(5) Only eight were developed with an EPP of 
>20, chiefly those predicting a broader outcome like ‘all stillbirth’ or ‘all antepartum stillbirth’. This 
EPP is based on a generalisation and for a rare outcome like stillbirth, fewer EPP may be sufficient. 
For example, if stillbirth prevalence were 1% (and in many contexts it is lower), then around 4 EPP 
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large concern about overfitting, even acknowledging the low prevalence of stillbirth. These included 
all models predicting stillbirth >37 weeks. Other concerns in analysis were inappropriately 
categorised predictors; BMI, age and UtAPI were all frequently categorised when they could have 
been continuous. Where continuous variables were used, few reported assessment for non-linearity. 
Missing data were handled by complete case analysis, with only one study using multiple 
imputation.(20) 
Most studies reported model discrimination, but only three included a description of model calibration. 
(20,21,32) Kayode presented calibration plots and reported the mean absolute error, Payne 
presented calibration plots and tested ‘goodness-of-fit’ using the Hosmer-Lemeshow method while 
Trudell explored calibration in terms of centiles of probability but did not present calibration plots or 
formal assessment of calibration. Four studies used internal validation incorporating bootstrapping to 
assess for optimism. (20,21,29,32) Two studies updated the models based on their findings. No 
other studies described internal validation.
Nine reports gave the model equation; overall 15 models were reported with the intercept and 
coefficients.  A further three were made available for use on a web portal but the algorithms were not 
provided.(23,25,27) 
The only models with an overall low risk of bias (20) were developed for use in low resource country 
settings using only clinical information, and, as might be expected, apparent model performance was 
lower than in models including ultrasound and biomarkers. Moreover, this model is likely to require 
recalibration to be generalisable.  
Model performance
Model performance was most frequently described using AUC.  The best performing model 
(maternal characteristics, ultrasound and PlGF in the second trimester to predict placentally 
associated stillbirth <32 weeks) reported excellent apparent discrimination with AUC 0.990 (0.983-
0.998).(23) This model was at high risk of bias because it used an effective sample size of 90 events, 
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Direct comparison of model performance was limited by the fact that each were developed in 
different datasets with different populations and contexts. In general, second and third trimester 
models had better apparent discrimination than earlier models. Models incorporating biomarkers and 
ultrasound findings had higher performance than maternal characteristics alone. (Figure S2) One 
model incorporating solely ultrasound variables (estimated fetal weight [EFW], cerebroplacental ratio 
[CPR] and femur length [FL]) in the third trimester in a high risk population had a reported AUC of 
0.88 (0.77-0.99) in the development dataset, superior to many incorporating maternal characteristics 
with or without biomarkers, although it was also at high risk of bias. (30) Although discrimination was 
higher the more specific the outcome chosen 
(“placentally-associated stillbirth <32 weeks” rather than “all stillbirth”) these models were also likely 
to be limited by small sample sizes and low EPP. Figure 3 shows the AUC of models predicting a) 
“all stillbirth” and b) “stillbirth >37 weeks”. No studies considered net benefit, reported positive 
predictive values (PPV) or directly evaluated clinical impact or utility. Trudell et al.(32) included a 
brief assessment of cost effectiveness assuming that the model would be used to triage patients for 
non-stress test (NST) monitoring and that this might reduce stillbirth, although this is not supported 
by existing evidence.(36) Calibration was rarely reported, and optimism-adjusted calibration 
measures (i.e. adjusted for overfitting) not considered. Calibration plots, where provided, did suggest 




This review identified 69 models predicting stillbirth, none of which were externally validated. There 
are substantial concerns about risk of bias and applicability precluding the recommendation of any 
identified model for clinical practice at present. The best apparent performance was reported in 
models developed for use in later pregnancy incorporating maternal characteristics, placental 










This article is protected by copyright. All rights reserved
Several candidate predictors were consistently selected for inclusion in model development and may 
be important in development of new models. These include ethnicity, maternal BMI, PAPP-A, PlGF 
and UtAD. 
Strengths and limitations 
This study provides a broad overview of existing models utilising a comprehensive literature search 
with a methodologically robust assessment of risk of bias and applicability of included models, in 
accordance with best practice reporting guidelines. 
Direct quantitative comparison of the models included was prevented by the heterogenous predictors 
and outcomes utilised. A more direct comparison of model performance could be made by external 
validation of models in an independent dataset. None of the identified models has yet undergone 
external validation and updating (e.g. recalibration for particular populations). In order to perform 
independent external validation, the definition of predictors and outcomes and the details of the 
model algorithm (including intercept and coefficients) are required. Nine models identified are 
amenable to external validation in suitable datasets. 
All of the included models raised concern about either risk of bias or applicability, with a high risk of 
bias in all but two models. Common concerns related to low EPP, inappropriate modelling of 
continuous variables or handling of missing data, lack of internal or external validation. Given that 
few model developers undertook internal validation it was not possible to describe the relationship 
between model optimism and EPP. The apparent performance of reported models must be 
considered in the light of lack of adjustment for optimism and incomplete reporting, meaning that 
most were likely to be overfitted. An overfitted model is unlikely to translate into an effective clinical 
tool, and may cause harm through inaccurate predicted risks. 
Two models were at low risk of bias,(20) but were developed in a low resource setting and less 
applicable to higher resource settings. These models would be suitable for external validation and 
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In all included models, biochemical variables were included as Multiples of the Median (MoMs), 
commonly used to adjust for laboratory and gestational variance. There have been concerns raised 
that this adjustment(37) may lead to loss of data and overfitting. Novel model development protocols 
include these predictors without adjustment.(38) 
The predictive accuracy of a model for predicting stillbirth by a fixed gestation over time is affected by 
the ‘competing risk’ of live birth. One group undertook time-to-event analysis of the proportional 
hazards associated with abnormal UtAD pulsatility index,(39) treating live births as censored. This 
improved discrimination at later gestations, but assumes that censoring was unrelated to prognosis. 
In fact, women with known risk factors (predictors) for stillbirth are probably systematically delivered 
earlie, leading to a treatment paradox. This effect is likely present in all routinely collected datasets, 
and unless accounted for, any prediction model for stillbirth >37 weeks will appear to have limited 
accuracy. This is critical because this is a key time frame when a prediction model could have 
significant clinical impact - the most effective intervention to prevent stillbirth remains scheduled birth, 
usually only pragmatic at term. 
Interpretation 
The AFFIRM trial tested active management of reduced fetal movement for the prevention of stillbirth 
but was unable to show a benefit, although intervention increased.(40) This highlights the urgency of 
accurately identifying women at increased risk in order to minimise iatrogenic harm. Still, developing 
new models for the prediction of stillbirth is resource intensive, requiring large datasets with high 
quality information on predictors and interventions. In the seven years since a review identified three 
models for the prediction of stillbirth,(1) a further 66 have been published. Would the resources 
required to develop more models be justified when these have yet to be validated, updated and 
assessed in practice?
Future research should focus on validation and updating of existing first trimester models before 
subjecting them to clinical evaluation, while development of new second/third trimester models 
should be a priority. New model development should adhere to reporting guidelines and 










This article is protected by copyright. All rights reserved
A two-step triage model might be most appropriate - first trimester models with high sensitivity could 
select a large group for additional monitoring or intervention (e.g. low-dose aspirin). Later pregnancy 
models could incorporate fetal information (e.g. maternal and fetal Doppler indices and growth) and 
occurrence of pregnancy complications to give individualised assessment of risk by gestation. 
Maternal ethnicity was consistently included as a predictor, but variable definitions lead to concern 
about generalisability. Ethnicity is consistently associated with both maternal and perinatal mortality, 
(41,42) but is likely confounded by socio-economic status, structural racism and health literacy. The 
finding that ethnicity modifies risk of stillbirth is important, and policy makers need this information to 
underline the importance of increasing population health and equity of access to quality healthcare in 
reducing stillbirth. Nonetheless, a variable that is inconsistently defined by researchers, applied 
unpredictably by participants to themselves (43) and increasingly complex with successive 
generations is arguably inherently unsuitable for precise prediction models. 
Stillbirth is a heterogenous outcome related to several pathophysiological pathways. It is implausible 
that a single test will have high sensitivity for all-cause stillbirth. Prioritisation of sensitivity may lead 
to clinically useful tests being discarded. This may be best addressed by separate models; logically, 
the initial target could be placental dysfunction, the largest contributor to global stillbirth. 
Development of a core outcome set for stillbirth might help to specify outcomes for future models. (44) 
Consideration should be given to the timing of the outcome predicted. All included models 
considered stillbirth as a binary outcome – present or absent at a given gestation. It appeared that 
the earlier that gestation, the better the performance, but this should be examined in the light of 
clinical utility. A model predicting stillbirth <32 weeks may have high sensitivity, but is likely to have 
such a poor PPV that pre-emptive delivery would lead to an unacceptable degree of iatrogenic 
prematurity. The population incidence affects the PPV of the test, so that even with a high apparent 
performance the PPV may be as low as 1-3%. The level of risk that justifies intervention is a clinical 
decision that should be made together with individual women. 
Conclusion 
This systematic review has identified 69 models incorporating maternal characteristics, biomarkers 









This article is protected by copyright. All rights reserved
and not yet suitable for use in practice. Future research should focus on the validation of predictive 
performance (calibration and discrimination) and testing of clinical impact of first trimester models, 
the development of novel models for use in the third trimester to facilitate individualised mode and 
timing of birth discussions and development of large, publicly accessible datasets suitable for 
external validation of existing models. Clinical benefit should also be evaluated, using net benefit and 










This article is protected by copyright. All rights reserved
Acknowledgements
Jane Sandall is an NIHR Senior Investigator and is also supported by the National Institute for Health 
Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at 
King’s College Hospital NHS Foundation Trust. The views expressed are those of the author[s] and 
not necessarily those of the NIHR or the Department of Health and Social Care.
Disclosure of interests
AH reports grants from Tommy’s and Action Medical Research, outside the submitted work. 
BWM reports grants from the National Health and Medical Research Council (NHMRC) and personal 
fees from Obseva, Merck, Merck Merck KGaA, Guerbet and iGenomix, outside the submitted work.
GCS reports grants and personal fees from GlaxoSmithKline Research and Development Limited, 
grants from Sera Prognostics Inc, non-financial support from Illumina Inc, grants, personal fees and 
non-financial support from Roche Diagnostics Ltd, outside the submitted work.  In addition, GCS was 
a named inventor on a patent application submitted by Cambridge Enterprise for a biomarker test to 
predict human fetal growth restriction pending.
JS reports support from the NIHR Applied Research Collaboration South London, outside the 
submitted work. 
RT, AK, RR and ST report receipt of a grant from the Stillbirth and Neonatal Death Society (SANDS) 
during the conduct of this study. 
AM, JA, LJ, LM, PvD, MP and KS have no disclosures.
Completed disclosure of interest forms are available to view online as supporting information.
Contribution to authorship 
RT planned and carried out the data extraction and analysis and wrote the first draft of the 
manuscript. AM carried out data extraction and analysis and reviewed and edited the manuscript. JA, 
KS and RR contributed to study design, interpretation of the results and reviewed and edited the 
manuscript. ST and AK conceived the project, contributed to study design and reviewed and edited 
the manuscript. AH, LAM, PvD, GS, JS, BM and BT contributed expertise in stillbirth and prediction 
model development and reviewed and edited the manuscript. LJ is a patient representative and MP 
represents parents who have experience of stillbirth via Sands and they consulted on design and 










This article is protected by copyright. All rights reserved
Details of ethics approval 
This was a systematic review of previously published data and as such did not require formal ethics 
approval. 
Funding 
The authors are collaborators in the IPPIC (International Prediction of Pregnancy Complications) 
stillbirth project, funded by Sands (the Stillbirth and Neonatal Death Society). 
REFERENCES
1. Kleinrouweler CE, Cheong-See F, Collins G, Kwee A, Thangaratinam S, Khan KS, et al. 
Prognostic models in obstetrics: available, but far from applicable. Am J Obstet Gynecol. 
2016;214(1):79–90. 
2. Blencowe H, Cousens S, Jassir FB, Say L, Chou D, Mathers C, et al. National, regional, and 
worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. 
Lancet Glob Heal. 2016 Feb 1;4(2):e98–108. 
3. Widdows K, Roberts S, Camacho E, Heazell A. Evaluation of the implementation of the Saving 
Babies ’ Lives Care Bundle in early adopter NHS Trusts in England. Manchester, UK; 2018. 
4. Moons KGM, Groot JAH De, Bouwmeester W, Vergouwe Y, Mallett S. Critical Appraisal and 
Data Extraction for Systematic Reviews of Prediction Modelling Studies : The CHARMS 
Checklist. PLOS Med. 2014;11(10). 
5. Wollf R, Whiting P, Mallett S, Riley R, Westwood M, Kleijnen J, et al. PROBAST: a risk of bias 
tool for prediction modelling studies. In: Cochrane Colloqium. Vienna; 2015. 
6. Riley R, van der Windt D, Croft P. Prognosis Research in Healthcare: Concepts, Methods and 
Impact. Oxford, UK: Oxford University Press; 2019. 
7. Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. 
Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 
2013;10(2):e1001381. 
8. Tavares Da Silva F, Gonik B, McMillan M, Keech C, Dellicour S, Bhange S, et al. Stillbirth: 









This article is protected by copyright. All rights reserved
immunization safety data. Vaccine. 2016/07/16. 2016 Dec 1;34(49):6057–68. 
9. Debray TPA, Damen JAAG, Snell KIE, Ensor J, Hooft L, Reitsma JB, et al. A guide to 
systematic review and meta-analysis of prediction model performance. BMJ. 2017 
Jan;356:i6460. 
10. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol. 2009 
Oct;62(10):1006–12. 
11. Geersing G-J, Bouwmeester W, Zuithoff P, Spijker R, Leeflang M, Moons K. Search Filters for 
Finding Prognostic and Diagnostic Prediction Studies in Medline to Enhance Systematic 
Reviews. PLoS One. 2012 Feb 29;7(2):e32844. 
12. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. J Am Med Inform 
Assoc. 2001;8(4):391–7. 
13. Steyerberg EW. Clinical Prediction Models. New York, NY: Springer New York; 2009. 
(Statistics for Biology and Health). 
14. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number 
of events per variable in logistic regression analysis. J Clin Epidemiol. 1996 Dec 
1;49(12):1373–9. 
15. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox 
regression. Am J Epidemiol. 2007 Mar;165(6):710–8. 
16. Courvoisier DS, Combescure C, Agoritsas T, Gayet-Ageron A, Perneger T V. Performance of 
logistic regression modeling: beyond the number of events per  variable, the role of data 
structure. J Clin Epidemiol. 2011 Sep;64(9):993–1000. 
17. Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Moons KGM, et al. Minimum sample size 
for developing a multivariable prediction model: Part I - Continuous outcomes. Stat Med. 2018 
Oct 22; 
18. van Smeden M, de Groot JAH, Moons KGM, Collins GS, Altman DG, Eijkemans MJC, et al. 
No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. BMC 
Med Res Methodol. 2016 Nov 24;16(1):163. 
19. Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Moons KGM, et al. Minimum sample size 
for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. 
Stat Med. 2018;(February):1–21. 









This article is protected by copyright. All rights reserved
Predicting stillbirth in a low resource setting. BMC Pregnancy Childbirth. 2016;16(1):1–8. 
21. Payne BA, Groen H, Ukah UV, Ansermino JM, Bhutta Z, Grobman W, et al. Development and 
internal validation of a multivariable model to predict perinatal death in pregnancy 
hypertension. Pregnancy Hypertens. 2015;5:315–21. 
22. Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH. Maternal serum placental 
growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. 
Ultrasound Obstet Gynecol. 2008 Nov;32(6):732–9. 
23. Aupont JE, Akolekar R, Illian A, Neonakis S, Nicolaides KH. Prediction of stillbirth from 
placental growth factor at 19–24 weeks. Ultrasound Obstet Gynecol. 2016;48:631–5. 
24. Vellamkondu A, Vasudeva A, Bhat RG, Kamath A, Amin S V., Rai L, et al. Risk Assessment at 
11–14-Week Antenatal Visit: A Tertiary Referral Center Experience from South India. J Obstet 
Gynecol India. 2017;67(6):421–7. 
25. Akolekar R, Tokunaka M, Ortega N, Syngelaki A, Nicolaides KH. Prediction of stillbirth from 
maternal factors, fetal biometry and uterine artery Doppler at 19–24 weeks. Ultrasound Obstet 
Gynecol. 2016;48(5):624–30. 
26. Yerlikaya G, Akolekar R, Mcpherson K, Syngelaki A, Nicolaides KH. Prediction of stillbirth from 
maternal demographic and pregnancy characteristics. Ultrasound Obstet Gynecol. 
2016;48:607–12. 
27. Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH. Prediction of stillbirth from 
placental growth factor at 11–13 weeks. Ultrasound Obstet Gynecol. 2016;48:618–23. 
28. Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH. Prediction of stillbirth from 
biochemical and biophysical markers at 11 – 13 weeks. Ultrasound Obstet Gynecol. 
2016;48:613–7. 
29. Åmark H, Westgren M, Persson M. Prediction of stillbirth in women with overweight or 
obesity—A register-based cohort study. PLoS One. 2018;13(11):1–11. 
30. Khalil A, Morales-Rosellõ J, Townsend R, Morlando M, Papageorghiou A, Bhide A, et al. 
Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors 
of stillbirth and perinatal loss. Ultrasound Obstet Gynecol. 2016;47(1). 
31. Familiari A, Scala C, Morlando M, Bhide A, Khalil A, Thilaganathan B. Mid-pregnancy fetal 
growth, uteroplacental Doppler indices and maternal demographic characteristics: role in 
prediction of stillbirth. Acta Obstet Gynecol Scand. 2016;95(11):1313–8. 









This article is protected by copyright. All rights reserved
& internal validation of a clinical prediction model to quantify stillbirth risk. PLoS One. 
2017;12(3):1–13. 
33. Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH. Prediction of miscarriage and 
stillbirth at 11 – 13 weeks and the contribution of chorionic villus sampling. Prenat Diagn. 
2011;31:38–45. 
34. Kingdon C, Roberts D, Turner MA, Storey C, Crossland N, Finlayson KW, et al. Inequalities 
and stillbirth in the UK: a meta-narrative review. BMJ Open. 2019 Sep 1;9(9):e029672. 
35. van Smeden M, Moons KG, de Groot JA, Collins GS, Altman DG, Eijkemans MJ, et al. Sample 
size for binary logistic prediction models: Beyond events per variable criteria. Stat Methods 
Med Res. 2018 Jul 3;096228021878472. 
36. Grivell RM, Alfirevic Z, Gyte GML, Devane D. Antenatal cardiotocography for fetal assessment. 
Cochrane database Syst Rev. 2015 Sep;2015(9):CD007863. 
37. Bishop JC, Dunstan FD, Nix BJ, Reynolds TM, Swift A. All MoMs are not equal: some 
statistical properties associated with reporting results in the form of multiples of the median. 
Am J Hum Genet. 1993 Feb;52(2):425–30. 
38. Mackie FL, Whittle R, Morris RK, Hyett J, Riley RD, Kilby MD. First-trimester ultrasound 
measurements and maternal serum biomarkers as prognostic factors in monochorionic twins: 
a cohort study. Diagnostic Progn Res. 2019;3(9):1–9. 
39. S Smith GC, H Yu CK, Papageorghiou AT, Maria Cacho A, Nicolaides KH. Maternal Uterine 
Artery Doppler Flow Velocimetry and the Risk of Stillbirth LEVEL OF EVIDENCE: II. Vol. 109, 
Obstet Gynecol. 2007. 
40. Norman JE, Heazell AEP, Rodriguez A, Weir CJ, Stock SJE, Calderwood CJ, et al. 
Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a 
stepped wedge, cluster-randomised trial. Lancet. 2018;392(10158):1629–38. 
41. Muglu J, Rather H, Arroyo-Manzano D, Bhattacharya S, Balchin I, Khalil A, et al. Risks of 
stillbirth and neonatal death with advancing gestation at term: A systematic review and meta-
analysis of cohort studies of 15 million pregnancies. Smith GC, editor. PLOS Med. 2019 Jul 
2;16(7):e1002838. 
42. Knight M, Bunch K, Tuffnell D, Shakespeare J, Kotnis R, Kenyon S, et al. Saving Lives, 
Improving Mothers’ Care Lessons learned to inform maternity care from the UK and Ireland 
Confidential Enquiries into Maternal Deaths and Morbidity 2015-17. Oxford, UK; 2019. 









This article is protected by copyright. All rights reserved
pregnancy according to the gestation-related optimal weight classification : a cross-sectional 
study. BJOG. 2018;125:704–9. 
44. Duffy JMN, Ziebland S, von Dadelszen P, McManus RJ. Tackling poorly selected, collected, 











This article is protected by copyright. All rights reserved
Figures and Tables 
Table 1: Predictors included in the final models provided in each paper
Figure 1. PRISMA flow diagram 
Figure 2a. PROBAST risk of bias
Figure 2b. PROBAST applicability 
Figure 3a. Model performance for “all stillbirth” outcome
Figure 3b. Model performance for “stillbirth >37 weeks” outcome
Online Supporting Material
Table S1. Characteristics of included studies
Table S2. Ethnicity categories in the included prediction models 
Table S3. Variation in outcomes chosen for included stillbirth prediction models
Figure S1. Number of models by year of publication
Figure S2. AUC distribution by predictor types included in the model 
Appendix S1. Literature search strategy June 2019










This article is protected by copyright. All rights reserved
Table 1. Predictors included in the final models provided in each paper 







































































































































































Akolekar 2011 ● ● ● ● ● ● ● ● ●
Akolekar 2016 (1) ● ● ● ● ● ● ● ● ● ●
Akolekar 2016 (2) ● ● ● ● ● ● ● ● ● ● ●
Aupont 2016 ● ● ● ● ● ● ● ● ● ● ●
Amark 2018 ● ● ● ● ● ●
Familiari 2016 ● ● ● ● ●
Kayode 2016 ● ● ● ● ● ● ● ●
Khalil 2016 ● ● ●
Mastrodima 2016 ● ● ● ● ● ● ● ● ● ● ●
Payne 2015 ● ● ●
Smith 2007 ● ● ●
Trudell 2017 ● ● ● ● ● ● ●
Vellamkondu 2017 ● ● ●

























Figure 2a. PROBAST risk of bias
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Figure 2b. PROBAST Applicability 
 
Figure 3a. Model performance for “all stillbirth” outcome 
The figure shows the apparent area under the curve (AUC) with their 95% confidence intervals 
reported for models predicting “all stillbirth” or “all antepartum stillbirth”  
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Figure 3b. Model performance for stillbirth at term  
The figure shows the area under the curved (AUC) with their 95% confidence intervals reported 
for models predicting stillbirth >37 weeks 
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